Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Debate 48A Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 48B Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 49A What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 49B What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 50A Should Adjuvant Radiation be Given to Women with Single Node Positive Vulvar Cancer?
- Debate 50B Should Adjuvant Radiation Therapy be Given to Patients with Single Node Positive Vulvar Cancer?
- Debate 51A Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Debate 51B Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Index
- References
Debate 48B - Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
Radiation Therapy
from Section VI - Vaginal and Vulvar Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Debate 48A Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 48B Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 49A What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 49B What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 50A Should Adjuvant Radiation be Given to Women with Single Node Positive Vulvar Cancer?
- Debate 50B Should Adjuvant Radiation Therapy be Given to Patients with Single Node Positive Vulvar Cancer?
- Debate 51A Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Debate 51B Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Index
- References
Summary
Sentinel lymph node (SLN) biopsy is now the standard of care over inguinofemoral lymphadenectomy (IFL) in properly selected patients with early-stage squamous cell carcinoma (SCC) of the vulva. Patients with negative SLN do well without further intervention. However, a standardized treatment paradigm following the findings of a positive SLN remains lacking. Based on results from the GROINSS-V-II trial, patients with a micrometastasis of ≤2 mm receiving adjuvant inguinofemoral radiation therapy had a two-year ipsilateral isolated groin recurrence rate of 1.6%, and can avoid the morbidity of complete inguinofemoral lymphadenectomy (IFL). The approach for patients with SLN macrometastases (>2 mm) remains undefined – if such patients are treated without further IFL, careful attention to radiation treatment planning, dose, and the addition of concurrent cisplatin-based chemotherapy should be considered.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 294 - 296Publisher: Cambridge University PressPrint publication year: 2023
References
American Cancer Society. Cancer Facts & Figures 2022. Atlanta, GA: American Cancer Society, 2022.Google Scholar
Van der Zee, AG, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008;26(6):884–889.CrossRefGoogle ScholarPubMed
Te Grootenhuis, NC, et al. Sentinel nodes in vulvar cancer: long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol 2016;140(1):8–14.CrossRefGoogle Scholar
Levenback, CF, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. J Clin Oncol 2012;30(31):3786–3791.CrossRefGoogle ScholarPubMed
Oonk, MHM, et al. Radiotherapy versus inguinofemoral lymphadenectomy as treatment for vulvar cancer patients with micrometastases in the sentinel node: results of GROINSS-V II. J Clin Oncol 2021;39(32):3623–3632.CrossRefGoogle ScholarPubMed
Glaser, S, et al. Inguinal nodal radiotherapy for vulvar cancer: are we missing the target again? Gynecol Oncol 2014;135(3):583–585.CrossRefGoogle Scholar
Montana, GS, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 2000;48(4):1007–1013.CrossRefGoogle ScholarPubMed